"Patient Advocacy Spurs Eli Lilly to Address Zepbound Shortage for Obesity Treatment"

TL;DR Summary
Patients are struggling to access the weight-loss shot Zepbound due to a shortage of the pre-filled pens used to administer the drug, prompting calls for Eli Lilly & Co. to release more supply. The company's CEO cited the complexity of production systems as a factor contributing to the shortage.
Reading Insights
Total Reads
0
Unique Readers
0
Time Saved
0 min
vs 1 min read
Condensed
39%
80 → 49 words
Want the full story? Read the original article
Read on Bloomberg